Return to search results.
Complete title: An Open-label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigators Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)
|Research Study Number||20121582|
|Principal Investigator||Ryan Cassaday|
Research Study Description
Eligibility Criteria (must meet the following to participate in this study)
Other eligibility criteria may apply.
Hematologic Malignancies; Leukemia; Lymphoproliferative Disease
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.